<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089452</url>
  </required_header>
  <id_info>
    <org_study_id>CP-01/09</org_study_id>
    <secondary_id>HREC/10/Alfred/5</secondary_id>
    <secondary_id>62/10</secondary_id>
    <nct_id>NCT01089452</nct_id>
  </id_info>
  <brief_title>Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study</brief_title>
  <acronym>ACCESS</acronym>
  <official_title>ACCESS STUDY (Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study) ARB/CCB Combination Therapy: Efficacy vs an ACE-inhibitor/CCB Combination and Use as First Line Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Monash University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking to evaluate which drug combination, olmesartan/amlodipine or&#xD;
      perindopril/amlodipine, is better at lowering blood pressure in people with mild to moderate&#xD;
      hypertension. The investigators will be enrolling people who are either currently taking&#xD;
      medication to lower their blood pressure or who have been recently diagnosed with high blood&#xD;
      pressure and are not yet on medication.&#xD;
&#xD;
      Patients on medication for their blood pressure will be asked to stop taking this medication&#xD;
      for 2 to 4 weeks. If their blood pressure is suitable (not too high or low) they will be&#xD;
      randomised to one of their treatment arm:&#xD;
&#xD;
      Group 1 will receive Perindopril on its own (5mg for 4 weeks followed by 10mg for 8 weeks).&#xD;
      There will be 80 patients in this group.&#xD;
&#xD;
      Group 2 will receive Perindopril and Amlodipine together (5mg/5mg for 4 weeks, 10mg/5mg for a&#xD;
      further 4 weeks then 10mg/10mg for the final 4 weeks). There will be 80 patient in this&#xD;
      group.&#xD;
&#xD;
      Group 3 will receive Olmesartan and Amlodipine together (20mg/5mg for 4 weeks, 40mg/5mg for a&#xD;
      further 4 weeks then 40mg/10mg for the final 4 weeks). There will be 120 patients in this&#xD;
      group.&#xD;
&#xD;
      During the study we will measure the patients blood pressure and heart rate, weight and&#xD;
      perform routine blood tests. They will also have ECGs (3 occasions) and 24 hour blood&#xD;
      pressure monitor (4 occasions).&#xD;
&#xD;
      At the end of the study patients pre-study medication will be restarted or they will be put&#xD;
      on to a suitable alternative.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study not started due to administrative reasons.&#xD;
  </why_stopped>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood pressure between the groups</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute cardiovascular risk</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measurements will be performed at baseline and 12 weeks of key variables that contribute to absolute cardiovascular risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>12 weeks</time_frame>
    <description>Frequency of drug-related adverse events and major cardiovascular events.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Perindopril monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perindopril/amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olmesartan/amlodipine FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril</intervention_name>
    <description>Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks</description>
    <arm_group_label>Perindopril monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril/amlodipine</intervention_name>
    <description>Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.</description>
    <arm_group_label>Perindopril/amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan/amlodipine</intervention_name>
    <description>Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.</description>
    <arm_group_label>Olmesartan/amlodipine FDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Over 18 years of age&#xD;
&#xD;
          2. Has provided written informed consent&#xD;
&#xD;
          3. Mild to moderate hypertension (WHO Stage 1-2). Patients with mild to moderate&#xD;
             hypertension will be either de novo presenters with this condition or withdrawn from&#xD;
             background antihypertensive therapy for a period of 2 weeks. If sSBP is not greater&#xD;
             than 140 mmHg after this 2 week withdrawal period (*130 mmHg if diabetes or CKD, as&#xD;
             per Heart Foundation of Australia Hypertension Guidelines 20082), patients can be&#xD;
             followed, off therapy, for a further 2 weeks in order to meet this criterion. If their&#xD;
             systolic blood pressure is above 180 mmHg they will be withdrawn from the study and&#xD;
             will be provided with appropriate treatment.&#xD;
&#xD;
          4. Hypertensive patients with a high level of risk, i.e. having at least one of the&#xD;
             following risk factors :&#xD;
&#xD;
               -  History of CV event eg MI, stroke (&gt;6 months ago)&#xD;
&#xD;
               -  History of revascularization procedure (&gt;6 months ago)&#xD;
&#xD;
               -  Impaired kidney function (eGFR &lt;70 ml/min)&#xD;
&#xD;
               -  ECG or echocardiographic evidence of LV hypertrophy&#xD;
&#xD;
               -  Obesity, defined as BMI &gt;30 kg/m2&#xD;
&#xD;
               -  Diabetes mellitus&#xD;
&#xD;
               -  Peripheral arterial disease&#xD;
&#xD;
               -  Macroalbuminuria&#xD;
&#xD;
               -  Current smoking (defined as smoking at least 7 cigarettes per week)&#xD;
&#xD;
          5. Women must be post menopausal or using an acceptable method of contraception i.e.&#xD;
             surgical sterilisation, hormonal contraception or double barrier method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Secondary causes of hypertension (e.g. Conn's Syndrome, renal artery stenosis)&#xD;
&#xD;
          2. Serum creatinine &gt;0.25 mmol/L or eGFR &lt;40 ml/min&#xD;
&#xD;
          3. Serum potassium &gt;5.5 mmol/L&#xD;
&#xD;
          4. Abnormal LFTs (i.e. serum transaminases &gt;2x ULN)&#xD;
&#xD;
          5. Sitting SBP &gt;180 mmHg&#xD;
&#xD;
          6. Recent (&lt;6 months) MI, CVA, TIA, revascularisation procedure&#xD;
&#xD;
          7. Ethanol abuse (in the opinion of the investigator)&#xD;
&#xD;
          8. Concomitant drug therapy that may impact on BP e.g. NSAIDs, COX-2 inhibitors, other&#xD;
             antihypertensive agents&#xD;
&#xD;
          9. Unable to comply with study requirements (in the opinion of the investigator)&#xD;
&#xD;
         10. Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Krum, MBBS FRACP PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash University / Alfred Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <name_title>Prof Henry Krum</name_title>
    <organization>Monash University / Alfred Hospital</organization>
  </responsible_party>
  <keyword>Mild to moderate hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Perindopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

